TAU researchers develop new treatment for rare genetic disorder

Written on |

Adolescents and young adults with familial adenomatous polyposis bear a high risk of developing cancer

Researchers from Tel Aviv University and Tel Aviv Sourasky Medical Center (Ichilov Hospital) have developed an innovative drug treatment for familial adenomatous polyposis (FAP), a rare, inherited condition that affects adolescents and young adults and often leads to colorectal cancer. The novel drug, based on antibiotics, inhibits the development of intestinal polyps that, left untreated, become cancerous. In a preliminary clinical trial, the condition of seven out of eight patients who completed the full treatment improved dramatically. The research was jointly led by Prof. Rina Rosin-Arbesfeld of the Department of Microbiology and Clinical Immunology at TAU’s Sackler School of Medicine and Prof. Revital Kariv of the Sackler School and the Department of Gastroenterology at Tel Aviv Sourasky Medical Center. FAP, which is characterized by multiple polyps along the gastrointestinal tract, especially in the large bowel, is caused by a mutation in the adenomatous polyposis coli (APC) gene. These mutations are also crucial for colorectal cancer development.

Why does FAP lead to colon cancer?

“To prevent the development of colorectal cancer, FAP patients are closely monitored via frequent colonoscopies to locate and remove their polyps,” Prof. Rosin-Arbesfeld says. “However, some patients must have their colons removed at a very young age, which dramatically affects their quality of life.” In its normal state, APC promotes the production of a protein that inhibits cancer development. But mutations to the APC gene produce an inactive protein that is unable to prevent the development of the polyps. In some FAP patients, the mutations in the APC gene are what are called “nonsense mutations.” “Each sequence of three nucleotides in the DNA is a code that tells the cell to produce a certain amino acid, which are the building blocks of the proteins produced in the body’s cells,” Prof. Rosin-Arbesfeld explains. “At the end of the protein coding sequence, there is usually a ‘stop codon’ to stop the protein production. But in FAP patients with a nonsense mutation, the APC’s stop codon appears prematurely, so the protein production stops prematurely, creating an inactive protein.”

Preventing surgical intervention

Previous experiments on cell cultures and mouse models in Prof. Rosin-Arbesfeld’s laboratory revealed that certain types of antibiotics caused cells to “ignore” the mutation stop codon and a normal protein resulted. These trials yielded promising results that led to the clinical trial at Tel Aviv Sourasky Medical Center. “Since the relevant antibiotics were already approved for human use, we decided to move directly from the laboratory to the clinic and to examine the treatment of FAP patients,” says Prof. Rosin-Arbesfeld. In the clinical study carried out by Prof. Kariv and Dr. Shlomi Cohen, director of the Pediatric Gastroenterology Unit at Dana-Dwek Children’s Hospital, 10 FAP patients received the novel antibiotic therapy. Eight of them completed the treatment, which lasted four months. Colonoscopies performed during and after the treatment showed that in seven patients the polyps significantly decreased in number. Moreover, the positive effects of the treatment were evident a year after it began. “Our goal as therapists, in addition to preventing cancer, is to improve the quality of life of our patients and their families and to enable them to live as full and normal lives as possible,” Prof. Kariv concludes. “The new therapeutic approach we are developing may allow patients to delay surgical intervention or even prevent it entirely.” The researchers recently won Tel Aviv University’s SPARK grant, which supports the development of applied research.

Related posts

Aerobic Activity can Reduce Risk of Metastatic Cancer by 72%

15 November 2022

4th Covid-19 Vaccine Reduces Risk of Death by 72% Amongst Elderly

21 July 2022

Going to the Beach? Sun Exposure Makes Men Hungrier than Women

19 July 2022

Breakthrough Technology Could Lead to One-Time HIV Treatment

14 June 2022

TAU Researchers Find Gene Mechanism Linked to Autism and Alzheimer’s

26 May 2022

Want to Live Longer? Find Out if You Snore

15 May 2022

TAU Researchers Invent Healthy Weapon Against Covid

15 April 2022

Is the Vaccine Safe? Consult the Smart Sensor!

12 April 2022

TAU Nanodrug Enables 2-in-1 Attack on Cancer

6 April 2022

TAU Welcomes Ukrainian Emergency Fellowship Students

1 April 2022

Prof. Ehud Gazit – First Israeli to Receive Prestigious International Recognition in Chemistry

1 April 2022

Minor Head Injury Leads to Chronic Post-Concussion Syndrome in 1 of 4 Children

29 March 2022

Inventive Study to Develop Biological Solutions for Agriculture

28 March 2022

TAU Technology Could Prevent Repeat Heart Valve Surgery

25 March 2022

Israeli Breakthrough in Treating PTSD

22 February 2022

Discovery May Enable Early Diagnosis of Alzheimer’s

15 February 2022

Victoria

Tok Corporate Centre, Level 1,
459 Toorak Road, Toorak VIC 3142
Phone: +61 3 9296 2065
Email: office@aftau.asn.au

New South Wales

P.O. Box 4044, Maroubra South,
NSW 2035
Phone: +61 418 465 556
Email: davidsolomon@aftau.org.au

Western Australia

P O Box 36, Claremont,
WA  6010
Phone: :+61 411 223 550
Email: clivedonner@thelinqgroup.com